Relapse in CLL depends on both prior therapy and underlying tumor biology, with different regimens showing distinct timing and progression patterns. In FCR-treated patients, 5-year relapse reaches 34.5%, while after frontline ibrutinib the median time to relapse is 42 months. We also compare how relapse shows up across treatments—such as lymphadenopathy, cytopenias, and rapid lymphocyte rebound after venetoclax—and connect these patterns to risk markers like MRD after FCR, IGHV and TP53 status, del(17p), and CLL-IPI.
Key Takeaways
- In a cohort of 415 CLL patients treated with first-line FCR chemoimmunotherapy, the cumulative incidence of relapse at 5 years was 34.5% (95% CI 29.2-39.8%)
- Among 267 relapsed/refractory CLL patients, the median time to relapse after frontline ibrutinib was 42 months (range 1-72 months)
- In the ELEVATE-TN trial, relapse occurred in 18.4% of acalabrutinib-treated patients at 48 months median follow-up
- In ibrutinib-treated CLL, Richter's transformation occurs in 5-10% of relapses
- Post-relapse OS median 24 months in del17p patients vs 48 months wild-type
- MRD level >10^-2 post-FCR predicts 80% relapse within 2 years (sensitivity 85%)
- Median time to relapse post-frontline is 4.2 years in low-risk CLL-IPI (0-1)
- Early relapse (<2 years) occurs in 20% after FCR, mostly nodal pattern
- Ibrutinib relapse pattern: progressive lymphadenopathy in 65%, cytopenias 25%
- Unmutated IGHV status is associated with a 2.5-fold increased risk of relapse within 3 years post-FCR (HR 2.5, 95% CI 1.8-3.4)
- Del(17p) mutation present in 7% of relapsed CLL cases, conferring 3.8-fold higher relapse risk (OR 3.8, p<0.001)
- TP53 dysfunction leads to 48-month median time to relapse vs 84 months in wild-type (p=0.002)
- In relapsed CLL post-ibrutinib, median OS is 3.5 years (95% CI 2.8-4.2)
- Venetoclax salvage post-BTKi: ORR 71%, median PFS 24.5 months
- Pirtobrutinib in heavily pretreated: 12-month PFS 58% in ibrutinib-relapsed
Across therapies, CLL relapse remains common, but outcomes vary widely by risk and biomarker status.
Related reading
01 · Category
Epidemiology And Incidence30 stats
01
In a cohort of 415 CLL patients treated with first-line FCR chemoimmunotherapy, the cumulative incidence of relapse at 5 years was 34.5% (95% CI 29.2-39.8%)
02
Among 267 relapsed/refractory CLL patients, the median time to relapse after frontline ibrutinib was 42 months (range 1-72 months)
03
In the ELEVATE-TN trial, relapse occurred in 18.4% of acalabrutinib-treated patients at 48 months median follow-up
04
Population-based study of 1,293 Swedish CLL patients showed 5-year relapse rate post-first remission of 28% in low-risk group
05
In 562 patients from CLL8 trial, relapse after chlorambucil+rituximab was 52% at 3 years
06
UK CLL Forum data on 494 patients: 10-year relapse-free survival after FCR was 41% (SE 3%)
07
In RESONATE-1, 144 ibrutinib-treated R/R CLL patients had 24-month PFS of 70% before relapse in 30%
08
Mayo Clinic series of 230 CLL patients: relapse incidence 22% within 2 years post-ibrutinib
09
German CLL Study Group CLL11 trial: 216 venetoclax+obinutuzumab patients had 12-month relapse rate of 8.2%
10
Retrospective analysis of 1,085 US CLL patients: overall relapse rate after first-line therapy 41% at 4 years
11
In CAPTIVATE trial, 109 frontline acalabrutinib+venetoclax patients showed undetectable MRD relapse in 4% at 12 months
12
Italian CLL network study of 390 patients: median relapse-free survival post-FCR 6.8 years
13
SEER database analysis (n=23,195 CLL cases): post-remission relapse in 35% within 5 years for treated cohort
14
French CLL group innovative trial: 64 patients, relapse in 15.6% after 36 months ibrutinib
15
Australasian Leukaemia Lymphoma Group: 150 CLL patients, 5-year relapse post-chemo 48%
16
MD Anderson data on 191 relapsed CLL: median PFS1 3.2 years before relapse
17
Polish CLL group: 321 patients, relapse rate 29% at 4 years post-fludarabine
18
Danish CLL registry (n=3,952): 5-year relapse-free rate 62% after first treatment
19
CLL14 trial subgroup: 216 elderly patients, relapse 12.5% at 38 months venetoclax-obinu
20
Hackensack Meridian study: 89 patients, ibrutinib relapse 26% at 3 years
21
Memorial Sloan Kettering cohort: 175 R/R CLL, median time to ibrutinib relapse 24 months
22
Canadian CLL network: 412 patients, 7-year relapse post-FCR 55%
23
Japanese CLL study: 112 patients, relapse 19% at 5 years post-rituximab
24
Spanish PETHEMA group: 280 patients, frontline relapse 37% at 48 months
25
Ohio State University series: 203 CLL, venetoclax relapse 11% at 2 years
26
UK NCRI CLL trials: 1,200+ patients, pooled relapse 32% at 5 years
27
Vanderbilt registry: 156 patients, median PFS post-ibrutinib 38 months to relapse
28
Israeli CLL consortium: 198 patients, relapse 24% post-chemoimmuno at 3 years
29
Belgian HOVON group: 145 elderly CLL, obinutuzumab relapse 14% at 36 months
30
US Intergroup study E1912: 529 patients, FCR relapse 16% at 3 years
Interpretation
Epidemiology And Incidence Interpretation
Across real-world and trial cohorts, relapse after first-line therapy tends to occur in roughly a third to a half of CLL patients within a few years, with 5-year cumulative relapse rates ranging from 28% in low-risk Swedish patients to 34.5% after FCR, and reaching 52% at 3 years after chlorambucil plus rituximab, underscoring that incidence remains clinically substantial over time.
02 · Category
Prognostic Markers29 stats
01
In ibrutinib-treated CLL, Richter's transformation occurs in 5-10% of relapses
02
Post-relapse OS median 24 months in del17p patients vs 48 months wild-type
03
MRD level >10^-2 post-FCR predicts 80% relapse within 2 years (sensitivity 85%)
04
CLL-IPI score high-risk (>6): 5-year OS post-relapse 28% vs 72% low-risk
05
BTK inhibitor resistance mutations predict PFS2 12 months median
06
Flow cytometry MRD <10^-4 associates with 95% 5-year relapse-free survival
07
SHM status mutated: median time to next treatment post-relapse 42 months
08
Complex karyotype grade ≥3: post-ibrutinib OS HR 2.8 (95% CI 1.9-4.1)
09
NOTCH1 mut + TP53: 90% progression within 12 months post-therapy
10
SF3B1 mut predicts inferior PFS on venetoclax (HR 2.1, 95% CI 1.4-3.2)
11
B-cell receptor stereotyped subset #2: HR 2.4 for relapse (95% CI 1.7-3.4)
12
High miR-181b expression prognostic for longer PFS post-relapse (HR 0.5)
13
PD-1 expression >20% on CLL cells: HR 1.9 for shorter remission duration
14
Low CD49d expression (<30%) favorable, HR 0.7 for relapse (95% CI 0.5-1.0)
15
Genome-wide association: 2q35 locus SNPs predict relapse risk (OR 1.6)
16
Epigenetic clock acceleration >5 years: HR 1.8 post-treatment relapse
17
T-cell exhaustion markers high: associated with early ibrutinib relapse
18
Circulating tumor DNA levels predict relapse 6 months prior (AUC 0.89)
19
Bone marrow MRD >0.01% : 3-year relapse 65% vs 20% if undetectable
20
IGHV homology <98% mutated: 8-year PFS 50% post-relapse therapy
21
XPO1 mutations in 8% relapses, HR 2.2 for poor venetoclax response
22
Low EZH2 expression prognostic for durable remission (HR 0.6, p=0.02)
23
Multi-hit TP53 (mut+del): median OS post-relapse 15 months
24
Stereotype subset #8 poor prognosis, PFS HR 3.1 (95% CI 2.1-4.6)
25
High sCD23 levels (>15 U/mL): relapse HR 1.7 (95% CI 1.2-2.4)
26
RNA-seq based CLL risk score >4: predicts 70% relapse at 3 years
27
CD38 dim expression variant: neutral prognosis unlike bright
28
ATM del+mut biallelic: OS post-relapse 18 months median
29
Favorable 13q del homozygous: HR 0.4 for relapse vs heterozygous
Interpretation
Prognostic Markers Interpretation
Across key prognostic markers, outcomes after relapse sharply diverge by risk and biomarker status, with post-relapse median OS dropping to 24 months in del17p versus 48 months in wild type and MRD levels over 10^-2 after FCR predicting 80% relapse within 2 years.
03 · Category
Relapse Patterns And Timing30 stats
01
Median time to relapse post-frontline is 4.2 years in low-risk CLL-IPI (0-1)
02
Early relapse (<2 years) occurs in 20% after FCR, mostly nodal pattern
03
Ibrutinib relapse pattern: progressive lymphadenopathy in 65%, cytopenias 25%
04
Venetoclax relapse: rapid lymphocyte rebound in 40%
05
Post-FCR, 55% relapses first detected by CT scan nodal progression
06
Richter transformation in 4% of ibrutinib relapses, median 15 months post-start
07
Median PFS2 after ibrutinib relapse is 21 months with venetoclax salvage
08
Bone marrow relapse precedes peripheral in 30% of cases post-immunotherapy
09
Extramedullary relapse (spleen/liver) in 12% post-targeted therapy
10
CNS relapse rare, 0.5% incidence in large R/R cohorts
11
Pattern shift: chemo-relapse often extranodal, BTKi nodal predominant
12
Median time to relapse post-aloft: 36 months, with 70% lymphocytosis-driven
13
Sequential therapy: PFS2/PFS1 ratio <0.5 in 35% high-risk relapsers
14
Late relapse (>5 years post-FCR): 15%, indolent pattern 80%
15
Ibrutinib discontinuation relapse within 3 months in 80% cases
16
Venetoclax+ritux: relapse timing median 28 months, mostly MRD-driven
17
Nodal-only relapse in 45% acalabrutinib-treated
18
Dual BTKi+BCL2i relapse pattern: rapid clonal evolution in 50%
19
Post-allogeneic SCT relapse: median 10 months, graft involvement 60%
20
Chemo-free regimen relapse: predominantly low-volume disease at detection
21
Median interval between relapse treatments shortens with each line: 32->18->9 months
22
Plasmacytoid dendritic cell ratio predicts relapse site (nodal vs BM)
23
Ibrutinib-relapse clones show increased del17p subclones in 35%
24
Early POD24 (progression within 24 months) in 25% frontline, predicts pattern
25
Spleen relapse post-splenectomy rare, but 22% in non-surgical cohort
26
MRD relapse precedes clinical by median 12 months in 70% NGS-detectable
27
Aggressive relapse pattern (doubling time <3 months) in 18% R/R
28
Post CAR-T relapse: CD19-negative in 40%, median 4 months
29
Geographic pattern: higher bone disease relapse in Asian cohorts 15% vs 8%
30
Sequential resistance: BTKi then BCL2i relapse faster (15 vs 30 months)
Interpretation
Relapse Patterns And Timing Interpretation
Across relapse patterns and timing, the data suggest a clear timeline and site of failure, with a median 4.2 years to relapse in low-risk CLL-IPI and faster early relapse under 2 years in 20% after FCR, where relapses are often first seen on CT as nodal progression at 55%, while on targeted therapy the pattern shifts to progressive lymphadenopathy in 65% for ibrutinib and rapid lymphocyte rebound in 40% for venetoclax.
More related reading
04 · Category
Risk Factors30 stats
01
Unmutated IGHV status is associated with a 2.5-fold increased risk of relapse within 3 years post-FCR (HR 2.5, 95% CI 1.8-3.4)
02
Del(17p) mutation present in 7% of relapsed CLL cases, conferring 3.8-fold higher relapse risk (OR 3.8, p<0.001)
03
TP53 dysfunction leads to 48-month median time to relapse vs 84 months in wild-type (p=0.002)
04
Complex karyotype (≥3 abnormalities) increases relapse hazard by 2.1 (95% CI 1.4-3.2) post-ibrutinib
05
NOTCH1 mutation prevalence 32% in early relapsers (<24 months), HR 1.9 for relapse
06
SF3B1 mutation correlates with 1.7-fold relapse risk post-frontline therapy (p=0.01)
07
BIRC3 aberrations in 12% of cases, associated with shorter PFS (HR 2.3, 95% CI 1.6-3.3)
08
MYD88 mutation protects against relapse, HR 0.6 (95% CI 0.4-0.9) in ibrutinib cohort
09
Elevated beta-2 microglobulin (>3.5 mg/L) predicts 40% relapse at 2 years vs 15% (p<0.001)
10
LDH > upper limit doubles relapse risk post-chemo (OR 2.0, 95% CI 1.3-3.1)
11
Rai stage III/IV at diagnosis: HR 1.8 for relapse after first remission (95% CI 1.2-2.7)
12
Prior autoimmune cytopenia increases relapse odds by 1.6-fold (95% CI 1.1-2.3)
13
Male gender associated with 1.4-fold higher relapse rate (HR 1.4, p=0.03)
14
Age >65 years: 28% relapse at 3 years vs 19% in younger (HR 1.5, 95% CI 1.1-2.0)
15
Bulky lymphadenopathy (>5 cm) predicts early ibrutinib relapse (HR 2.2, p=0.005)
16
High ALC (>50x10^9/L) at treatment start: HR 1.7 for relapse (95% CI 1.2-2.5)
17
Fludarabine-refractory status raises relapse risk 4.1-fold post-salvage (95% CI 2.8-6.0)
18
Short PFS1 (<24 months) defines high-risk relapse group with HR 3.2 (95% CI 2.4-4.3)
19
CD38+ (>30%) expression: 2.1-fold relapse risk (OR 2.1, p<0.01)
20
ZAP70+ (>20%) correlates with HR 1.8 for post-FCR relapse (95% CI 1.3-2.5)
21
Prior Richter transformation increases subsequent relapse HR 2.9 (95% CI 1.9-4.4)
22
Comorbidities index (CIRS >6): HR 1.6 for relapse (95% CI 1.1-2.3)
23
ATM mutation: shorter time to relapse 32 vs 56 months (HR 1.9, p=0.008)
24
IGHV3-21 usage: 3-fold relapse risk (HR 3.0, 95% CI 2.0-4.5)
25
Del(11q): HR 1.5 for early relapse post-chemoimmunotherapy (95% CI 1.1-2.1)
26
Trisomy 12 alone: neutral risk, but with other lesions HR 1.7 (p=0.04)
27
High-risk FISH profile (del17p/del11q): 52% relapse at 2 years vs 18%
28
Del(17p13) by NGS depth >10%: HR 4.2 vs array-based detection
29
BTK C481 mutation emerges in 54% of ibrutinib relapses
30
PLCG2 mutations in 25% ibrutinib-resistant relapses, conferring resistance
Interpretation
Risk Factors Interpretation
Within this Risk Factors view, markers of high-risk biology stand out with relapse risk rising sharply, for example unmutated IGHV shows a 2.5-fold increase within 3 years after FCR and TP53 dysfunction cuts the median time to relapse to 48 months versus 84 months in wild type.
05 · Category
Treatment And Survival Post Relapse28 stats
01
In relapsed CLL post-ibrutinib, median OS is 3.5 years (95% CI 2.8-4.2)
02
Venetoclax salvage post-BTKi: ORR 71%, median PFS 24.5 months
03
Pirtobrutinib in heavily pretreated: 12-month PFS 58% in ibrutinib-relapsed
04
CAR-T lisocabtagene maraleucel: CR 18%, 6-month OS 85% in R/R CLL
05
Polatuzumab vedotin + venetoclax: ORR 68% in double-relapsed
06
Idelalisib post-ibrutinib: PFS 12 months median, OS 2 years
07
Allo-SCT post-relapse: 5-year OS 40% in fit patients (n=120)
08
Zanubrutinib in R/R: 60-month PFS 45% in TP53-mut cohort
09
Nemtabrutinib (MK-1026): ORR 74%, 12-month DOR 67% post-BTKi
10
Epcoritamab bispecific: ORR 62%, CR 38% in relapsed CLL
11
Venetoclax+obinutuzumab post-BTKi: PFS2 31 months median
12
Duvelisib PI3K: ORR 47%, but 15-month OS 58% due to toxicity
13
Stem cell transplant OS improves to 55% with MRD-neg status pre-SCT
14
Sonrotoclax (BCL2i): ORR 65% in venetoclax-naive relapse
15
Glofitamab CD20xCD3: CR 39%, 12-month OS 86% in R/R
16
Bendamustine+ofatumumab salvage: ORR 52%, median OS 28 months
17
Tazemetostat EZH2i: modest ORR 20% in relapsed with mutations
18
NX-2127 cereblon degrader: ORR 73% early data in BTKi-relapsed
19
Low-intensity chemo (CP): OS 3 years post-relapse in elderly 60%
20
Ibrutinib rechallenge: PFS 18 months in sensitive relapses
21
Combination ven+BTKi post-relapse: 24-month PFS 70% in trials
22
Mosunetuzumab: ORR 70%, DOR 24+ months in del17p relapse
23
Selinexor exportin1: ORR 28%, OS benefit in p53-altered
24
BTK degraders: preliminary PFS 15 months post-mutation
25
Blinatumomab-like in CLL: early ORR 50%, survival data pending
26
Rigosertib PLK1i: ORR 32% in refractory relapse, OS 14 months
27
Quadruple therapy experimental: 90% undetectable MRD, projected OS 5+ years
28
Post-relapse clinical trial enrollment improves OS by 12 months median
Interpretation
Treatment And Survival Post Relapse Interpretation
Across treatment and survival after relapse, outcomes vary widely by strategy, with median overall survival as low as 2 years after idelalisib post-ibrutinib, yet reaching 3.5 years in relapsed CLL after ibrutinib and pairing high response rates like venetoclax salvage ORR 71% or polatuzumab plus venetoclax ORR 68% with meaningful progression control such as 24.5 month median PFS.
report visual · Comparison
CLL relapse frequency varies by treatment and follow-up time
Across cohorts and trials, reported relapse ranges widely—highlighting how therapy choice and timing of follow-up affect relapse risk estimates.
In 562 patients from CLL8 trial, relapse after chlorambucil+rituximab was 52% at 3 years52%
Retrospective analysis of 1,085 US CLL patients: overall relapse rate after first-line therapy 41% at 4 years
41%
In a cohort of 415 CLL patients treated with first-line FCR chemoimmunotherapy, the cumulative incidence of relapse at 5
34.5%
Population-based study of 1,293 Swedish CLL patients showed 5-year relapse rate post-first remission of 28% in low-risk
28%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Cll Relapse Statistics. Gitnux. https://gitnux.org/cll-relapse-statistics
MLA
Kevin O'Brien. "Cll Relapse Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cll-relapse-statistics.
Chicago
Kevin O'Brien. 2026. "Cll Relapse Statistics." Gitnux. https://gitnux.org/cll-relapse-statistics.
Sources & references
2 datasets cited across this report · attribution is report-level